XENE
Xenon Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.24B
P/E Ratio
—
EPS
$-4.36
Beta
0.74
52W High
$63.95
52W Low
$28.19
50-Day MA
$52.70
200-Day MA
$42.79
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.06
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.
Fundamentals
| Revenue (TTM) | $7.50M |
| Gross Profit (TTM) | $-293.44M |
| EBITDA | $-370.53M |
| Operating Margin | -4974.00% |
| Return on Equity | -51.80% |
| Return on Assets | -32.60% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $7.27 |
| Price-to-Book | 9.01 |
| Price-to-Sales (TTM) | 699.18 |
| EV/Revenue | 627.05 |
| EV/EBITDA | 34.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $96.64M |
| Float | $78.36M |
| % Insiders | 0.11% |
| % Institutions | 90.97% |
Analyst Ratings
Consensus ($79.24 target)
3
Strong Buy17
BuyData last updated: 4/28/2026